MedWatch

Lundbeck CSO negative regarding growth hope's future in failed indication

The candidate Lu AF35700's failure against treatment-resistant schizophrenia disappoints Lundbeck as well as its shareholders, and the company's CSO gives up the candidate in this indication.

Foto: PR

Lundbeck's failed phase III study with the candidate Lu AF35700 was a hard blow for the Danish drug group, and it does not only reflect in the share price.

The company's own CSO, Anders Gersel Pedersen, is also disappointed in the drug's failure to show statistical superiority to the conventional therapy against treatment-resistant schizophrenia (TRS). That is, the candidate did not prove more efficient than the existing therapies.

Læs hele artiklen

Få 14 dages fri adgang.
Det kræver intet kreditkort.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier